Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study

1Hôpital Avicenne, Université Paris, Paris, France; 2Inserm U848, Institut Gustave Roussy, Villejuif, France; 3Institut Paoli Calmettes, Marseille, France; 4Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; 5Centre Hospitalo-Universitaire Nice, Nice, France; 6Hôpital de Jolimont, la Louviere, Belgium; 7Hôpital Cochin, Université Paris, Paris, France; 8Centre Hospitalo-Universitaire de Rouen, Rouen, France; 9Centre Hospitalo-Universitaire de Limoges, Limoges, France; 10Centre Hospitalo-Universitaire de Nantes, Nantes, France; and 11Groupe Francophone des Myelodysplasies

[1]  A. Stamatoullas,et al.  Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program , 2008 .

[2]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[3]  of lenalidomide , 2008 .

[4]  M. Gordon Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[5]  S. Nimer Myelodysplastic syndromes. , 2008, Blood.

[6]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[7]  J. Maciejewski,et al.  Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS). , 2007 .

[8]  J. Byrd,et al.  Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .

[9]  U. Germing,et al.  Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion. , 2007 .

[10]  B. Sander,et al.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.

[11]  A. List,et al.  Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome , 2007, Leukemia.

[12]  J. Lancet,et al.  Treatment of deletion 5q acute myeloid leukemia with lenalidomide , 2007, Leukemia.

[13]  A. Giagounidis,et al.  Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses , 2006, Annals of Hematology.

[14]  D. Steensma,et al.  Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome , 2006, Leukemia.

[15]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[16]  P. Schafer,et al.  Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. , 2006, Leukemia research.

[17]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[18]  U. Germing,et al.  Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup , 2005, Annals of Hematology.

[19]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[20]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Thall,et al.  Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.

[22]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[23]  S. E. Jacobsen,et al.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.

[24]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[25]  L. Michaux,et al.  5q-, twenty-five years later: a synopsis. , 1997, Cancer genetics and cytogenetics.

[26]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[27]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .